study | No. of patients | Gender M/F | Age (< 70/≥70) | Smoking status (C or F /N) | Treatment | Detecting Items for Drug-Resistance Mechanism |
---|---|---|---|---|---|---|
Uramoto H et al. [10] | 11 | 3/8 | 7/4 | 2/9 | gefitinib | T790 M, KRAS,PTEN MET amp, HGF status |
Kuiper JL et al. [11] | 66 | 14/52 | NA | 30/33a | erlotinib gefitinib | T790 M, SCLC, KRAS |
Sun JM et al. [12] | 70 | 18/52 | NA | 14/56 | erlotinib gefitinib | T790 M |
Li W et al. [13] | 54 | 29/25 | 49/5 | 7/47 | erlotinib gefitinib Icotinib | T790 M |
Sequist LV et al. [14] | 37 | 15/22 | 31/6 | NA | erlotinib gefitinib | T790 M, MET amp, SCLC, PIK3CA, EMT |
Kosaka T et al. [15] | 14 | 4/10 | NA | 6/8 | Gefitinib | T790 M, KRAS |
Oxnard GR et al. [16] | 93 | 33/60 | NA | 32/61 | erlotinib gefitinib | T790 M, MET amp, HER2 |
Hata A et al. [17] | 78 | 24/54 | 51/27 | 24/54 | erlotinib gefitinib | T790 M |
Chen HJ et al. [18] | 29 | 18/11 | 27/2 | 6/23 | erlotinib gefitinib | T790 M, MET amp |
Ji W et al. [19] | 26 | 10/16 | 21/5 | NA | gefitinib | T790 M, MET amp, AXL, EMT, CD56 |